Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D006332:Cardiomegaly / Q000139:chemically induced; D002404:Catheterization; D003326:Coronary Circulation / Q000187:drug effects; D004206:Disopyramide / Q000009:adverse effects / Q000494:pharmacology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005263:Femoral Artery; D005268:Femoral Vein; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D011802:Quinidine / Q000494:pharmacology; D014439:Tyramine / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D011725:Pyridines; D004206:Disopyramide; D011802:Quinidine; D007545:Isoproterenol; D009638:Norepinephrine; D014439:Tyramine